Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give written consent and take part voluntarily
• People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by laboratory testing, and whose cancer is at an advanced or limited-spread stage (stage IVA or oligometastatic stage IVB, according to the 2017 staging system)
• People whose life expectancy is estimated to be longer than 3 months
• People aged between 18 and 75 years old
• People with a general health and activity level that falls within a certain range (rated 0–2 on a standard medical scale, meaning able to carry out daily activities with little to no limitation — confirm with trial site)
• People who have never received any treatment for their oesophageal cancer before, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy
• People who have at least one tumour that can be measured on scans
• People whose blood counts and organ function (including blood cells, liver, and kidneys) meet specific minimum levels as measured by blood tests, without the use of blood-boosting medications in the 14 days before starting the trial (confirm with trial site for exact values)
• People who are willing to attend follow-up appointments and cooperate with the trial requirements

Who may not be able to join:

• People who have uncontrolled fluid build-up around the lungs, heart, or abdomen that requires repeated draining
• People who are in a poor nutritional state with a BMI below 18.5 kg/m² — though this may be reconsidered if nutritional support was successfully provided before enrolment and a senior investigator approves
• People who are experiencing significant gastrointestinal bleeding (more than 200ml per day)
• People who have deep ulcers, as determined by the investigating doctor
• People who have had an allergic reaction to monoclonal antibodies or to any of the study drugs (camrelizumab, paclitaxel, cisplatin, or other platinum-based drugs)
• People who have previously received, or are currently receiving, any radiation, chemotherapy, or other anti-cancer treatments for this cancer
• People who have been taking immune-suppressing medications or high-dose steroids (more than the equivalent of 10mg of prednisone per day) within the 2 weeks before starting the trial — low-dose inhaled or topical steroids may be acceptable in certain circumstances (confirm with trial site)
• People who have received a live vaccine within 4 weeks before starting the trial
• People who have had major surgery or a serious injury within 4 weeks before starting the trial
• People who have a history of active autoimmune diseases (such as autoimmune lung disease, bowel inflammation, autoimmune hepatitis, or certain thyroid conditions) — some conditions with full remission or managed with hormone replacement may be considered (confirm with trial site)
• People with a history of immune system deficiency, HIV, other immune deficiency conditions, or who have had an organ transplant or bone marrow transplant
• People with significant or poorly controlled heart conditions, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or serious irregular heartbeats that are not well controlled
• People who have had a serious infection within the 4 weeks before starting the trial, or who have signs of active lung inflammation or an active infection requiring antibiotics within the 14 days before starting (preventive antibiotic use may be acceptable — confirm with trial site)
• People with active tuberculosis, a history of active tuberculosis in the past year, or a history of tuberculosis that was not properly treated
• People with active hepatitis B or hepatitis C infections that meet specific viral load thresholds as measured by blood tests
• People who, in the opinion of the investigating doctor, have other serious medical or personal circumstances (including mental health conditions, alcohol or substance issues, or social factors) that could affect their safety or ability to participate in the trial

Important: Always verify eligibility with the trial site directly before applying.